Arbutus Biopharma (ABUS) EBITDA Margin (2013 - 2026)

Arbutus Biopharma has disclosed EBITDA Margin across 14 years of filings, most recently posting 94.68% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 94.68%, up 148680.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 83.94% (up 127660.0% YoY), and the FY2025 annual result was 237.62%, up 89079.0% from the prior year.
• EBITDA Margin came in at 94.68% for Q1 2026 at Arbutus Biopharma, up from 354.42% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 94.68% in Q1 2026 to a low of 1456.24% in Q3 2024.
• The 5-year median for EBITDA Margin is 363.96% (2023), against an average of 613.42%.
• Across the five-year window, EBITDA Margin slumped 103717 bps in 2024 and surged 148680 bps in 2026, its largest moves.
• Arbutus Biopharma's EBITDA Margin stood at 342.93% in 2022, then tumbled by 156 bps to 878.74% in 2023, then gained by 9 bps to 799.05% in 2024, then jumped by 56 bps to 354.42% in 2025, then soared by 127 bps to 94.68% in 2026.
• The last three EBITDA Margin figures came in at 94.68% (Q1 2026), 354.42% (Q4 2025), and 1452.55% (Q3 2025), per Business Quant data.